drugset
drugset / Trial / NCT04761185

Raltitrexed in HIPEC

NCT04761185 ↗

Phase 1 Completed 30 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the tolerance of patients with colorectal cancer to hyperthermic intraperitoneal chemotherapy with Raltitrexed, to determine the safety, tolerability, PK, and efficacy.

Timeline

Start
2020-09-18
Primary completion
2024-12-28
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltitrexed Small molecule 3 mg/m2 Other
Subject Raltitrexed Small molecule 4 mg/m2 Other
Subject Raltitrexed Small molecule 5 mg/m2 Other
Subject Raltitrexed Small molecule 6 mg/m2 Other
Subject Raltitrexed Small molecule 7 mg/m2 Other
Subject Raltitrexed Small molecule 8 mg/m2 Other
Subject Raltitrexed Small molecule 9 mg/m2 Other

Indications

colorectal cancer